Beta 1-selective adrenoceptor antagonists. 3. 4-Azolyl-linked phenoxypropanolamines

Area of Science:

• Medicinal Chemistry
• Pharmacology

Background:

• Development of selective beta-adrenoceptor antagonists is crucial for cardiovascular therapeutics.
• Cardioselectivity aims to minimize side effects associated with non-selective beta-blockade.

Purpose of the Study:

• To synthesize and evaluate novel 4-substituted phenoxypropanolamines for beta-adrenoceptor activity.
• To introduce cardioselectivity into beta-blocker candidates through specific structural modifications.

Main Methods:

• Synthesis of a series of 4-substituted phenoxypropanolamines.
• In vitro assessment of beta-adrenoceptor activity and selectivity.
• Structure-activity relationship (SAR) analysis.

Main Results:

• Several compounds exhibited potent beta 1-adrenoceptor blockade.
• Compounds 11, 21, and 22 demonstrated high cardioselectivity with selectivity ratios > 100:1.
• Optimal positioning of heteroatoms within the 4-substituent was identified.

Conclusions:

• Novel phenoxypropanolamine derivatives with significant beta 1-selective adrenoceptor antagonist properties were identified.
• The study provides insights into SAR for achieving cardioselectivity in beta-blockers.
• These findings may guide the development of improved cardiovascular medications.